BARD Score for NAFLD Fibrosis
ورودیهای بالینی بیمار
حداقل ۱۰ — حداکثر ۷۰ • واحد: kg/m²
حداقل ۱ — حداکثر ۵۰۰۰ • واحد: U/L
حداقل ۱ — حداکثر ۵۰۰۰ • واحد: U/L
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk0–1
- High Risk2–4
The BARD Score for NAFLD Fibrosis calculates predicting risk of advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). Key inputs include bmi. Scores guide managing portal hypertension complications, referring for liver transplant evaluation, and supportive care. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Predicts risk of advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). The BARD score uses three simple clinical parameters (BMI, AST/ALT ratio, and diabetes) to identify patients at low risk of advanced fibrosis who may not require liver biopsy.
Clinical Indication
The BARD Score for NAFLD Fibrosis is indicated for bedside clinical practice to support Predicts risk of advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). The BARD score uses three simple clinical parameters (BMI, AST/ALT ratio, and diabetes) to identify patients at low risk of advanced fibrosis who may not require liver biopsy.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with decompensated liver cirrhosis, acute liver failure, portal hypertension, ascites, or end-stage liver disease awaiting organ allocation. Clinical application is indicated across Hepatology clinics, liver transplant assessment centers, gastroenterology wards, and liver ICUs.
Limitations & Contraindications
Due to muscle wasting and reduced hepatic creatine synthesis, serum creatinine routinely underestimates renal dysfunction in cirrhosis.
Clinical Pearls & Action Plan
Preventing spontaneous bacterial peritonitis (SBP), managing variceal hemorrhage, and monitoring hepatic encephalopathy are top clinical priorities.
BARD Score = BMI ≥28 (1 point) + AST/ALT ratio ≥0.8 (2 points) + Diabetes (1 point)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| bmi | float | Yes | Body Mass Index (weight in kg / height in m²)(kg/m²) |
| ast | float | Yes | Aspartate aminotransferase (AST)(U/L) |
| alt | float | Yes | Alanine aminotransferase (ALT)(U/L) |
| diabetes | string | Yes | Presence of type 2 diabetes mellitus |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–1 | Low Risk | Low risk of advanced fibrosis |
| 2–4 | High Risk | High risk of advanced fibrosis |
Evidence-Based References (EBM)
- Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008 Oct;57(10):1441-7. doi: 10.1136/gut.2007.146019.DOI: 10.1136/gut.2007.146019
- Raszeja-Wyszomirska J, Szymanik B, Ławniczak M, Kajor M, Chwist A, Milkiewicz P, et al. Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterol. 2010 Jun 17;10:67. doi: 10.1186/1471-230X-10-67.DOI: 10.1186/1471-230X-10-67
- Cichoż-Lach H, Celiński K, Prozorow-Król B, Swatek J, Słomka M, Lach T. The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease. Med Sci Monit. 2012 Dec;18(12):CR735-40. doi: 10.12659/msm.883601.DOI: 10.12659/msm.883601